<DOC>
	<DOCNO>NCT01192243</DOCNO>
	<brief_summary>The purpose study examine efficacy safety gefitinib combinated Pemetrexed/Cisplatin advance non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Study Gefitinib Compared With Pemetrexed/Cisplatin Advanced Non-Small Cell Lung Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patients diagnose histologic , cytologic diagnosis IV nonsmall cell lung cancer Age 18 70 year old At least one target lesion diameter spiral CT ≥ 1 cm , common CT ≥ 2 cm , measure imaging tool ECOG 01 Expected life time longer 12 week Normal laboratory value : leucocyte≥ 4×109/L neutrophil≥ 1.5×109/L platelet≥100×109/L Hemoglobin≥ 10g/L ALT AST ≤2.5×ULN ( ≤5×ULN liver metastasis ) Patients use drug accord protocol Patients allergic pemetrexed cisplatin Patients receive radiotherapy biological treatment 4 week trial Uncontrolled hydrothorax hydropericardium neuropathy toxicity ≥ CTC 3 Severe symptomatic heart disease Active upper gastrointestinal ulcer digestive disfunction Severe infection metabolic disfunction Patients malignant tumor Uncontrolled brain metastasis Patients accept clinical trial Female patient pregnant lactation period , patient without contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Objective response rate</keyword>
	<keyword>Time Progression</keyword>
	<keyword>Quality Live</keyword>
</DOC>